Iterum Net Cash Flow from Operations from 2010 to 2024
| ITRM Stock | USD 1.58 0.15 10.49% |
Check Iterum Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Iterum main balance sheet or income statement drivers, such as Tax Provision of 521.7 K, Interest Income of 1 M or Depreciation And Amortization of 1.8 M, as well as many exotic indicators such as Price To Sales Ratio of 25 K, Dividend Yield of 0.0 or Days Sales Outstanding of 10.4 K. Iterum financial statements analysis is a perfect complement when working with Iterum Therapeutics Valuation or Volatility modules.
Iterum | Net Cash Flow from Operations |
About Iterum Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Iterum Therapeutics income statement, its balance sheet, and the statement of cash flows. Iterum Therapeutics investors use historical funamental indicators, such as Iterum Therapeutics's Net Cash Flow from Operations, to determine how well the company is positioned to perform in the future. Although Iterum Therapeutics investors may use each financial statement separately, they are all related. The changes in Iterum Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Iterum Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Iterum Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Iterum Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Iterum Therapeutics Correlation against competitors. You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Iterum Stock analysis
When running Iterum Therapeutics' price analysis, check to measure Iterum Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iterum Therapeutics is operating at the current time. Most of Iterum Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iterum Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iterum Therapeutics' price. Additionally, you may evaluate how the addition of Iterum Therapeutics to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is Iterum Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Iterum Therapeutics. If investors know Iterum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Iterum Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.96) | Quarterly Revenue Growth (1.00) | Return On Assets (0.64) | Return On Equity (3.55) |
The market value of Iterum Therapeutics PLC is measured differently than its book value, which is the value of Iterum that is recorded on the company's balance sheet. Investors also form their own opinion of Iterum Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Iterum Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Iterum Therapeutics' market value can be influenced by many factors that don't directly affect Iterum Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Iterum Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Iterum Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Iterum Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.